Trial Profile
Expanded Access Protocol of Patisiran for Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) With Polyneuropathy
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 19 Jul 2022
Price :
$35
*
At a glance
- Drugs Patisiran (Primary)
- Indications Amyloid polyneuropathy; Transthyretin-related hereditary amyloidosis
- Focus Expanded access; Therapeutic Use
- Sponsors Alnylam Pharmaceuticals
- 10 Aug 2018 Status changed from recruiting to completed.
- 25 Oct 2016 New trial record